vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Update

vTv Therapeutics Inc. (NASDAQ:VTVT) was the target of a large decrease in short interest in November. As of November 30th, there was short interest totalling 22,500 shares, a decrease of 17.3% from the November 15th total of 27,200 shares. Approximately 1.6% of the shares of the company are short sold. Based on an average daily volume of 31,300 shares, the days-to-cover ratio is presently 0.7 days.

vTv Therapeutics Stock Down 4.3 %

vTv Therapeutics stock opened at $15.03 on Friday. The business’s 50-day moving average price is $14.94 and its 200 day moving average price is $16.45. The firm has a market cap of $47.95 million, a price-to-earnings ratio of -3.32 and a beta of 0.67. vTv Therapeutics has a 52 week low of $7.38 and a 52 week high of $30.99.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in vTv Therapeutics stock. FMR LLC purchased a new position in vTv Therapeutics Inc. (NASDAQ:VTVT) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 178,200 shares of the biotechnology company’s stock, valued at approximately $2,402,000. FMR LLC owned approximately 5.92% of vTv Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 17.51% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Alliance Global Partners began coverage on vTv Therapeutics in a research report on Monday, December 9th. They set a “buy” rating and a $35.00 price target for the company.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.